Media Thread, page-16463

Hi Godiva,

regarding your post that PD1-Vaxx trial ph 2 is open, that is the one announced in December 2023. Took them about 1 year to get started. Not sure if that is fast or not but at least some hope for IMU holders that in the coming years something positive will happen with the B-cell tech.

ASX Announcement 06 December 2023
New PD1-Vaxx Phase 2 Colorectal Cancer Clinical Trial
to Open in UK and Australia
• New PD1-Vaxx Phase 2 colorectal (CRC) cancer clinical trial to commence in
2024
• Approximately 10 sites, 6 in Australia and 4 in the UK with approximately 44
patients to be enrolled in the study over about 18 months
• Investigator Sponsored Study (IST) clinical trial to be conducted by the Cancer
Research UK Southampton Clinical Trials Unit at the University of Southampton
in collaboration with Royal Surrey Hospital NHS Foundation Trust and The
Australasian Gastro-Intestinal Trials Group (AGITG)
• Primary objective is to determine major pathological response rates, a
measurement of tumour size, after treating with PD1-Vaxx before surgery to
remove any residual tumour also known as neoadjuvant in operable CRC cancer
patients

BTW, at the RAD AGM PH was so kind to answer my question. Here the part that applies to IMU and CHM as well:

- they are aware of who sells and buys
- admitted that uncertainty about funding has been / is dragging his 3 stocks down but is surprised that this is still a problem at RAD as there is no funding problem at all
- all assets are progressing well and faster than average trials across all oncology fields
- for RAD: NASDAQ listing is still on track before end '24, 1 NASDAQ for 200 ASX

ATM I am a non-holder IMU / CHM due to above mentioned funding uncertainty but if PH can apply and find funds like at RAD I would consider
reentering.